Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
adults
children infants |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
M09AX10
|
| gptkbp:brand |
gptkb:Evrysdi
|
| gptkbp:CASNumber |
2035720-61-4
|
| gptkbp:chemicalFormula |
C22H23N7O
|
| gptkbp:developer |
gptkb:PTC_Therapeutics
gptkb:Genentech gptkb:Roche |
| gptkbp:form |
oral solution
|
| gptkbp:genericName |
gptkb:risdiplam
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evrysdi
|
| gptkbp:indication |
treatment of spinal muscular atrophy in patients 2 months and older
|
| gptkbp:legalStatus |
prescription only
Rx-only |
| gptkbp:mechanismOfAction |
SMN2 splicing modifier
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fever
diarrhea urinary tract infection rash mouth ulcers |
| gptkbp:usedFor |
spinal muscular atrophy
|
| gptkbp:bfsParent |
gptkb:Zolgensma
|
| gptkbp:bfsLayer |
5
|